- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Fasenra PhIII OSTRO trial met co-primary endpoints
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Farxiga reduces CKD progression and risk of death
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for small cell lung cancer
AnnouncementREG - AstraZeneca PLC - Ph I trial begins for COVID-19 monoclonal antibody
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in Japan for SCLC
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Imfinzi US Priority Review; four-week, fixed dose
AnnouncementREG - AstraZeneca PLC - AstraZeneca prices a $3bn bond issue
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Tagrisso US BTD for EGFRm adjuvant lung cancer
AnnouncementREG - AstraZeneca PLC - AZN: H1 2020 results
AnnouncementREG - AstraZeneca PLC - Board Committee Changes
AnnouncementREG - AstraZeneca PLC - Farxiga DAPA-CKD trial met all endpoints
AnnouncementREG - AstraZeneca PLC - Calquence receives positive CHMP opinion for CLL
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for EU approval in SCLC
AnnouncementREG - AstraZeneca PLC - AstraZeneca enters collaboration in oncology
AnnouncementREG - AstraZeneca PLC - Breztri Aerosphere approved in the US for COPD
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
Announcement